We are live on ! Find out more
LFCR icon

Lifecore Biomedical

98 hedge funds and large institutions have $287M invested in Lifecore Biomedical in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 38 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

22% more capital invested

Capital invested by funds: $235M → $287M (+$51.5M)

7% more funds holding

Funds holding: 9298 (+6)

1.15% more ownership

Funds ownership: 86.68%87.83% (+1.1%)

21% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 38

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $116K

Holders
98
Holders Change
+6
Holders Change %
+6.52%
% of All Funds
1.51%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.08%
New
17
Increased
30
Reduced
38
Closed
11
Calls
Puts
$116K
Net Calls
-$116K
Net Calls Change
-$29K
Name Holding Trade Value Shares
Change
Change in
Stake
AGM
101
Alpine Global Management
New York
-$181K -19,589 Closed
CS
102
Credit Suisse
Switzerland
-$162K -17,667 Closed
Arrowstreet Capital
103
Arrowstreet Capital
Massachusetts
-$92K -10,014 Closed
Zurich Cantonal Bank
104
Zurich Cantonal Bank
Switzerland
-$38K -4,174 Closed
Canada Life
105
Canada Life
Manitoba, Canada
-$13K -1,380 Closed
Simplex Trading
106
Simplex Trading
Illinois
-$3.76K -387 -92%
Osaic Holdings
107
Osaic Holdings
Arizona
-$3K -334 Closed
Toronto Dominion Bank
108
Toronto Dominion Bank
Ontario, Canada
+$29 +3 New

LFCR Hedge Fund Activity: Q4 2021 in Review

98 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2021, worth a combined $287M — up 22% from $235M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new LFCR positions and 11 closed out — a net gain of 6 holders — while 30 added to existing stakes and 38 trimmed.

The largest buyer was Assenagon Asset Management, adding an estimated $4.26M. The largest seller was Acuitas Investments, exiting entirely with an estimated $2.52M sold.

  • 98 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2021, up from 92 in Q3 2021.
  • Funds reported $287M of Lifecore Biomedical stock for Q4 2021, up 22% quarter-over-quarter.
  • 17 funds opened new Lifecore Biomedical positions in Q4 2021 and 11 closed out, a net change of +6 holders.
  • The largest Lifecore Biomedical buyer in Q4 2021 was Assenagon Asset Management, an estimated $4.26M added.
  • The largest Lifecore Biomedical seller in Q4 2021 was Acuitas Investments, an estimated $2.52M sold.

Based on aggregated 13F filings for Q4 2021.